Article Details
Retrieved on: 2017-12-13 22:00:51
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
<div>The immuno-oncology sector has yet another player. Kyn Therapeutics just made its debut after almost two years of gestation at <b>Atlas Venture</b> with three immuno-metabolism platforms and $49 million in first-round funding. Explaining the rationale behind the new company, CEO Mark Manfredi told us ...</div>
Article found on:
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here